

# Suprello™

## Surgical Wound Matrix




**SPARTAN®**  
M E D I C A L

### A peptide wound matrix designed to help prevent surgical site complications in high-risk cases


**Suprello™** Surgical Wound Matrix is specifically designed to help mitigate the risk of wound dehiscence at surgically created incision sites. The synthetically derived peptides in **Suprello™** form a resorbable wound matrix optimized for rapid tissue integration, intimate contact along incision margins, and antibacterial protection, supporting the closure of surgical wounds.

#### Rapid Tissue Integration



**Suprello™** Surgical Wound Matrix is formulated to rapidly resorb and integrate into the host tissue<sup>1,2</sup> to encourage healing by primary intention. **Suprello™** facilitates healing<sup>1,2</sup> at the re-approximated incision margins by supporting complete tissue apposition and sustained wound closure<sup>3</sup>.

#### Intimate Contact




The flowable peptide matrix offers optimal contact with the incision margins, creating an environment that supports healing<sup>2</sup> through primary intention<sup>3</sup>. Designed for the operating room, **Suprello™** system features a sterile, ready-to-use pre-filled syringe and flexible applicator tip<sup>2</sup> for precise delivery directly to the surgically created wound.

#### Antibacterial Protection




The cationic peptides in **Suprello™** provide inherent broad-spectrum antibacterial protection effective against multidrug-resistant organisms (MDROs)<sup>4,5</sup>, minimizing the risk of infection in high-risk surgical cases.



**Figure 1.** *In vitro*, **Suprello™** shows broad-spectrum antibacterial activity against gram-positive and gram-negative antibiotic-resistant clinical isolates<sup>4</sup>. *Enterococcus faecium* (USAISR); *Staphylococcus epidermidis* (USAISR); *Staphylococcus haemolyticus* (USAISR); MRSA: Methicillin-Resistant *Staphylococcus aureus*. (ATCC 33591); *Pseudomonas aeruginosa* (USAISR); *Escherichia coli* (USAISR); *Klebsiella pneumoniae* (USAISR); *Acinetobacter baumannii* (USAISR).

## Indications for Use

**Suprello™** is to be used under the supervision of health care professionals, for the local management of partial- and full-thickness surgical wounds.



## Product Presentation

DoD Ref. No.	Description	Wound Coverage
DLIN4059	Suprello™ Surgical Wound Matrix, 2-mL pre-filled syringe with applicator tip	20 cm <sup>2</sup>
DLIN4061	Volume Discount - Suprello™ Surgical Wound Matrix, 2-mL pre-filled syringe with applicator tip (4x units)	20 cm <sup>2</sup>

## References

1. Data on File (GM-2101); 2. FDA 510k submission package; 3. Data on File (TRS1702N); 4. Data on File (RR-0004); 5. Caetano B. et al. Wound Repair and Regeneration. 2025.

**LEARN MORE:**

Contact Spartan Medical Inc.



(888) 240-8091



CS@SPARTANMEDICAL.COM



**SPARTAN MEDICAL INC.**

1445 Research Blvd, Suite 520,  
Rockville, MD 20850

[spartanmedical.com](http://spartanmedical.com)

UEI: LCJBD88KQ8G3

DUNS: 807438341 | CAGE:65VT5

